TY  - JOUR
A1  - Wöbke, Thea Katharina
A1  - Sorg, Bernd L.
A1  - Steinhilber, Dieter
T1  - Vitamin D in inflammatory diseases
T2  - Frontiers in physiology
N2  - Changes in vitamin D serum levels have been associated with inflammatory diseases, such as inflammatory bowel disease (IBD), rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis (MS), atherosclerosis, or asthma. Genome- and transcriptome-wide studies indicate that vitamin D signaling modulates many inflammatory responses on several levels. This includes (i) the regulation of the expression of genes which generate pro-inflammatory mediators, such as cyclooxygenases or 5-lipoxygenase, (ii) the interference with transcription factors, such as NF-κB, which regulate the expression of inflammatory genes and (iii) the activation of signaling cascades, such as MAP kinases which mediate inflammatory responses. Vitamin D targets various tissues and cell types, a number of which belong to the immune system, such as monocytes/macrophages, dendritic cells (DCs) as well as B- and T cells, leading to individual responses of each cell type. One hallmark of these specific vitamin D effects is the cell-type specific regulation of genes involved in the regulation of inflammatory processes and the interplay between vitamin D signaling and other signaling cascades involved in inflammation. An important task in the near future will be the elucidation of the regulatory mechanisms that are involved in the regulation of inflammatory responses by vitamin D on the molecular level by the use of techniques such as chromatin immunoprecipitation (ChIP), ChIP-seq, and FAIRE-seq.
KW  - 1α,25(OH)2D3
KW  - VDR
KW  - cyclooxygenase
KW  - NFκB
KW  - NFAT
KW  - MKP1
KW  - interleukins
KW  - innate immune system
Y1  - 2014
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/51537
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-515374
VL  - 5
IS  - art. 244
PB  - Frontiers Research Foundation
CY  - Lausanne
ER  -